Treatment of Lupus Myelitis
Lupus myelitis requires immediate aggressive immunosuppression with IV methylprednisolone (500-1000 mg/day for 3-5 days) followed by IV cyclophosphamide, initiated within hours of presentation to prevent irreversible neurological damage. 1
Acute/Induction Treatment
The cornerstone of lupus myelitis management differs fundamentally from lupus nephritis protocols and demands urgent intervention:
First-Line Therapy
IV methylprednisolone pulse therapy: 500-750 mg (up to 1000 mg in adults) for 3 consecutive days, initiated immediately upon diagnosis 1
IV cyclophosphamide: Combined with methylprednisolone as the standard regimen 1, 3
- This combination shows effectiveness when administered promptly
- Neurological response typically occurs within days to 3 weeks, paralleled by MRI improvement 1
Oral glucocorticoids: Following IV pulse therapy, transition to oral prednisone 0.5 mg/kg/day, then taper gradually 1
Refractory Cases
For patients not responding to initial therapy:
Plasma exchange (plasmapheresis): Recommended for severe cases or inadequate response to first-line treatment 1, 4, 2
- Used successfully in multiple case series
- Consider early in patients with severe presentations
Rituximab: Emerging as an option for refractory disease 1, 4
- Case reports show rapid improvement in psychiatric and neurological manifestations
- Particularly useful when standard therapy fails
IVIG: Used in combination protocols, especially in pediatric cases 4
Special Considerations
Antiphospholipid antibody-positive patients: Add anticoagulation therapy, particularly if ischemic/thrombotic myelopathy is suspected 1
- This applies especially to patients not responding to immunosuppressive therapy alone
- Consider in those with optic neuropathy and altitudinal field defects
Neuromyelitis optica (NMO) overlap: If longitudinal extensive transverse myelitis (>3 spinal segments) is present:
- Test for serum NMO IgG (aquaporin-4) antibodies 1
- Consider complement inhibition (anti-C5 monoclonal antibody) for recurrent cases with persistent AQP4 positivity 5
- Newer agents like inebilizumab show promise for AQP4-positive cases 6
Maintenance Therapy
Critical to prevent relapses, which occur in 50-60% of patients during glucocorticoid taper 1, 2:
Chronic immunosuppressive therapy is mandatory following induction
Options include:
- Azathioprine (maintenance agent of choice historically)
- Mycophenolate mofetil
- Continued cyclophosphamide (though typically transitioned to less toxic agents)
IV cyclophosphamide during maintenance: Associated with delayed time to relapse 2
Prognostic Factors
Poor prognostic indicators requiring more aggressive therapy:
- Extensive spinal cord MRI lesions (>3 segments) 1
- Reduced muscle strength or sphincter dysfunction at presentation 1
- Hypoglycorrhachia (low CSF glucose) 2
- European Database for Multiple Sclerosis Grade Scale (EGS) ≥7 at nadir 2
- Delay in treatment initiation >2 weeks 1, 2
Expected outcomes:
- Sensory/motor recovery at 6 months: 75% of patients 2
- Complete recovery: Only 16% 2
- Most patients have residual disability despite treatment
- Only 20% develop chronic mild psychotic disorder when psychiatric symptoms present 1
Critical Diagnostic Pitfall
MRI-negative lupus myelitis (MNLM) exists but has worse outcomes 7, 8:
- Represents only 1% of lupus myelitis cases
- Normal spinal MRI and CSF does NOT exclude the diagnosis
- These patients show less favorable outcomes despite immunosuppressive therapy
- Consider functional neurological disorder if no improvement after restricted trial of immunosuppression
- Cervical cord localization predicts better complete recovery; thoracic involvement more common in new-onset SLE 8
Adjunctive Management
- Hydroxychloroquine: Continue as part of overall SLE management 1
- Acute inpatient rehabilitation: Physical therapy, occupational therapy, and speech therapy should begin early 4
- Marked functional improvement demonstrated in pediatric cases with coordinated rheumatology-rehabilitation approach
Key Clinical Algorithm
- Immediate recognition (within hours): Clinical suspicion of transverse myelitis in SLE patient
- Urgent MRI: Contrast-enhanced spinal cord imaging (detects T2 hyperintense lesions in 70-93%) 1
- CSF analysis: Rule out infection; expect mild-moderate abnormalities in 50-70% 1
- Initiate treatment immediately (do not wait for complete workup if infection ruled out):
- IV methylprednisolone 500-1000 mg daily × 3 days
- IV cyclophosphamide
- Assess for NMO overlap: If >3 segments involved, check AQP4 antibodies
- Add plasma exchange if inadequate response within days to 1 week
- Transition to maintenance immunosuppression to prevent relapse
- Anticoagulation if antiphospholipid antibodies positive
The evidence is clear: early aggressive treatment within hours to days is the single most important determinant of neurological outcome in lupus myelitis.